Typically, costs are reduced by using less material and floor space, and eliminating any specialty equipment required for handling large or heavy parts. For miniature devices, the equation is reversed.
Several alternatives exist to obtain FDA approval of artificial intelligence-enabled medical technology. Determining the best approach for a new device will require an awareness of each pathway’s specific requirements. An appreciation of the unique considerations for artificial intelligence-enabled technologies is another essential component of an efficient and effective application.
Embracing certification leads to enhanced product quality, innovation, and customer trust.
The new equity guide provides implementation steps to help developers and users implement the AHRQ Digital Healthcare Equity Framework to ensure new technologies ameliorate, rather than exacerbate, inequities in health care.
Information polarization affects public opinion. It can also affect investors. As we approach upcoming elections in different countries, it is crucial to understand how these political events could significantly reshape the landscape for MedTech investments. This article outlines an approach to help investors navigate and understand the interplay of political climates, cultural norms, and healthcare policies without getting emotionally attached to them. It emphasizes the importance of open dialogue, diversity, critical thinking, and cross-cultural collaborations to determine the true potential of MedTech innovations.
The push to use smaller packages can be counterproductive. The better solution may be to reduce the size of external components or eliminate them entirely and integrate their functionality into highly integrated ICs.
Product developers need to understand the technical challenges in device miniaturization but should be careful not to go beyond what is needed for the product. Sometimes further miniaturization is critical to the success of a product, sometimes it is superfluous, and sometimes it is even detrimental.
While pharmacogenomics has traditionally been the domain of academic research, policymakers are now showing a burgeoning interest in its potential to enhance patient outcomes and mounting evidence from the pharmaceutical industry is fueling interest in this field.
The healthcare sector can expect some improvement in lower inflation rates and attendant pressures for the remainder of 2024. But it’s not yet out of the pandemic woods, as interest rates remain high, the shortage of professionals persists and there’s no shortage of risks. Here’s a perspective on what the year holds.
Dave Bailey, VP of Consulting Services at Clearwater Security, highlights the need for top-down support in managing healthcare-related cyber risks and how the new NIST Cybersecurity Framework can help enhance cybersecurity in healthcare and MedTech organizations.
